Select Location
We need your delivery location to continue browsing
Prescription Required
bayer pharma
60 tablet
Sorafenib
Keep in cold place
Delivering To:
Overview
Nexavar 200mg Tablet is an anticancer medicine that helps to treat liver cancer that cannot be treated by surgery, advanced renal cell carcinoma (RCC), and certain types of thyroid cancer that spread to other parts of the body that cannot be treated with radioactive iodine.
Liver Cancer, Thyroid Cancer, Kidney Cancer
Thyroid cancer
Kidney cancer
Liver cancer
Most side effects of Nexavar 200mg Tablets do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Weakness
Tiredness
Hair loss
Itching
Loss of appetite
Diarrhea
Constipation
Weight loss
Dry mouth
Pain in the hand and feet
Joint pain
Headache Unusual bleeding
Blood in stools
Fever
Stomach pain
Nexavar 200mg Tablet is taken in tablet form twice a day or as per the doctor's prescription. Nexavar should be taken without food, two hours after or one hour before a meal. To get benefits soon, take this Tablet strictly according to the doctor's prescription. Taking this Tablet in the wrong way may give you severe side effects. The patients should take this medicine whole with water. If the patient feels well, then continue Nexavar; do not stop taking it without consulting the doctor.
Nexavar 200mg Tablet reduces tumor cells in the patient's body by blocking kinases who is responsible for tumor growth. Nexavar stops signaling, which will stop the growth and division of cancer cells in the patient's body. The benefits of the Tablet are seen in a few weeks or months depending on the health of the patients after starting treatment. However, to see the full benefit it can take several months or years. As to healthcare professionals. Nexavar is a powerful and very effective Tablet for the treatment of live cancer. However, it is important for patients to discuss of benefits and side effects at the beginning of treatment.
Alcohol
unsafe
It is advisable not to consume alcohol while taking medicine.
Pregnancy
consult your doctor
Do not take Nexavar 200mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not consume Nexavar 200mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If you forget to take a dose of Nexavar 200mg Tablet, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.
The Nexavar Tablet is used to treat liver cancer.
Store the medicine below 30 degrees temperature in a dry place.
Pregnant women should consult with their doctor first before taking cancer medicines as they can harm the unborn baby.
Self-medication is strictly prohibited. You are not allowed to take it without consulting the doctor.
Self-medication is strictly prohibited. You are not allowed to take it without consulting the doctor.
Arora, S. P., Moseley, J. L., Arellano, L. M., Salazar, M., Altermatt, B., Fuentes, L., Pham, V. T., Huang, G., Sun, L., Michalek, J., & Mahalingam, D. (2025, January 27). Phase II study of modulation of sorafenib‑induced autophagy using hydroxychloroquine in advanced hepatocellular cancer (HCC). Journal of Clinical Oncology, 43(4_suppl), 586. https://doi.org/10.1200/JCO.2025.43.4_suppl.586.
Author(s) unspecified. (2023). Real-world effectiveness and tolerability of sorafenib in unresectable hepatocellular carcinoma: A U.S. multicenter retrospective cohort study. OncoDaily.
Author(s) unspecified. (2024). Sorafenib plus hepatic arterial infusion chemotherapy vs sorafenib monotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Clinical Medicine.
Bayer HealthCare & Roche. (2024). Phase III randomized study of sorafenib plus erlotinib (SEARCH) versus sorafenib monotherapy in advanced hepatocellular carcinoma. Clinical Trial Protocol.
Fan, G., & Wei, X. (2025). Immune checkpoint inhibitor combinations versus sorafenib as first-line therapy in hepatocellular carcinoma: Systematic review and meta-analysis of clinical trials. Therapeutic Advances in Medical Oncology, 17, 1–14.